Keywords: Pfizer, Trubion, Rheumatoid arthritis, TRU-014, SB-087
Pfizer drops development of Trubion’s RA drug TRU-015, but will continue with SB-087
Article | 15 June 2010
US drug developer Trubion Pharmaceuticals says that partner Pfizer has decided to discontinue development of TRU-015 (PF-05212374), an investigational drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
